Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd.QNRX · Entity 7876 | Chief Financial Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quoin Pharmaceuticals Ltd.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ADSsSEC Table I · non-derivative | Direct | 10,684 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Purchase · Acquired 10,244 · Balance 10,684 F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. |
| Ordinary Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.10 | Direct | 5,122 |
Reported balance
After 2026-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-31 · Purchase · Acquired 5,122 · Balance 5,122 F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 01:39 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Warrants (Right to Buy) · Derivative | 5,122 | Not disclosed Strike: $6.10 | Not disclosed |
DisclosureSEC source: 0001104659-26-104403 · tm2624615-2_4seq1.xml · derivative · entry 2 Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,122 Underlying: ADS · 5,122 shares Expires not disclosed F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 01:39 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseADSs | 10,244 | $4.88 | $49,990.72 |
DisclosureSEC source: 0001104659-26-104403 · tm2624615-2_4seq1.xml · nonDerivative · entry 1 Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,684 F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:24 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 85,250 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001104659-26-011623 · tm265448-8_4seq1.xml · derivative · entry 1 Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,250 Underlying: ADS · 85,250 shares Expires 2036-02-04 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:39 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 10,330 | $0.00 Strike: $19.36 | $0.00 |
DisclosureSEC source: 0001104659-25-118190 · tm2532695-1_4seq1.xml · derivative · entry 1 Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,330 Underlying: ADS · 10,330 shares Expires 2035-12-01 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · date: The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.